Last updated: May 23, 2026
Hydrocortisone supply is fragmented across multiple global manufacturers that produce hydrocortisone API (or “hydrocortisone” USP/EP active) and contract fill-finish for creams, ointments, tablets, injectable suspensions, and ophthalmic preparations. Commercial availability is typically driven by (1) which dosage forms your market requires, (2) whether you need sterile manufacturing (injectables, ophthalmics), and (3) where your payer and regulator enforce compendial sourcing (USP/EP/BP) plus cGMP/DMF coverage.
Who supplies hydrocortisone API and who manufactures it under DMFs?
Hydrocortisone API is supplied by multiple established API makers and by branded “intermediates-to-finished” manufacturers that also carry API registrations. API availability is strongest for common strengths and dosage-form–linked grades (USP/EP), with tighter bottlenecks for sterile injectable suspension components (sterile micronized drug substance plus formulation-specific process controls).
API supply patterns by region
- US/EU compendial focus: firms that file or support DMFs and maintain batch traceability for hydrocortisone API used in creams, ointments, oral tablets, and sterile suspensions.
- India/China export footprint: large-scale API producers that supply international customers under cGMP and common compendial standards.
- Japan/Korea: contribute to select distribution channels and finished-dose coverage for local approvals.
What to map for an RFP (API)
- Compendial listing: USP/EP/BP grade compliance and relevant specifications
- Sterility relevance: non-sterile API for topical/oral vs sterile-ready internal processing for injectables
- Documentation: DMF/ASMF holder, ability to support regulatory filings, CoA format, and change control commitments
- Form-specific particle/process control: key for ophthalmic suspensions and injectable uniformity
Which companies supply hydrocortisone creams, ointments, and topical lotions?
Topical hydrocortisone is supplied by a mix of large branded generics companies, specialty dermatology brands, and contract manufacturers. In practice, the supply chain often routes through finished-dose manufacturers and repackagers who source hydrocortisone API plus excipients, then run semi-solid manufacturing under controlled viscosity, particle dispersion, and preservative compatibility.
Typical finished-dose manufacturers (topical)
The topical market is frequently supported by:
- Generic drug manufacturers with dermatology portfolios
- Specialty topical brands with US/EU footprints
- Contract manufacturers that offer semi-solid development and scale-up
Key sourcing risks for topical hydrocortisone
- Strength-specific formulation lock: 0.5%, 1%, 2.5% equivalents and vehicle differences drive distinct product specs and sometimes distinct IP
- Emollient and preservative selection: affects microbial control and stability
- Packaging compatibility: tube, jar, or pump formats change fill-finish requirements
Which suppliers make hydrocortisone tablets and oral suspensions?
Hydrocortisone oral supply is typically anchored by solid-dose manufacturers experienced in uniformity testing, blend homogeneity, and dissolution specs for low-dose vs higher-dose tablet strengths and oral suspension presentations.
What solid-dose suppliers must support
- Content uniformity and dissolution aligned to compendial monographs
- Manufacturing segregation for potency and cross-contamination controls
- Stability in suspension if supplying liquid dosage forms
Which companies supply sterile hydrocortisone injections and ophthalmic suspensions?
Sterile hydrocortisone supply is the hardest segment because it requires validated sterile manufacturing routes (aseptic processing, sterilizing filtration where applicable, terminal sterilization where applicable), sterile filling, and tight control of particulate matter and suspension uniformity.
Injectable supply chain characteristics
- Sterile suspensions: typically require controlled particle size distribution, suspension stability, and re-suspendability criteria
- Aseptic filling capability: and validated hold times for bulk-to-fill process
- Container closure system validation: vial stopper and seal integrity for sterility assurance
Ophthalmic supply chain characteristics
- Ocular sterility and preservative compatibility
- Particle size and suspension uniformity for visual tolerance
- Sterile filtration constraints: often limited by viscosity and particulate profile
How does hydrocortisone supplier coverage differ by dosage form (topical vs sterile)?
Featured differentiation in procurement is straightforward:
- Topical (cream/ointment/lotion): easier manufacturing scale, fewer sterile constraints, broader supplier pool
- Oral (tablets/suspensions): relies on solid dose and suspension stability capabilities
- Sterile injectable/ophthalmic: smaller qualified supplier set due to facility-level sterile QA and batch release constraints
What are the best-practice supplier qualification requirements for hydrocortisone?
A high-integrity qualification set for hydrocortisone sourcing covers regulatory documentation and operational reliability, not only price and lead time.
Regulatory and quality artifacts to require
- GMP compliance evidence for the manufacturing site
- API documentation (DMF/ASMF status or equivalent regulatory support package)
- CoA traceability and batch genealogy
- Stability protocol and release specs
- Change control transparency including formulation and process changes
Manufacturing controls to audit
- Particle size distribution and mixing validation for suspensions
- Microbiological controls for topical and sterile non-aseptic steps
- Cross-contamination controls for steroid handling
- Environmental monitoring and aseptic qualification for sterile lines
Supplier selection checklist for hydrocortisone procurement
- Dosage forms needed (topical, oral, injectable, ophthalmic)
- Sterile requirement (yes/no)
- Preferred compendial standard (USP/EP/BP)
- Regulatory support requirements (DMF/ASMF or site master file documentation)
- Batch size and lead time requirements
- Cold chain needs (generally limited but confirm for specific suspension formats)
- Packaging specs (tube, vial, bottle, blister)
- Audit history and inspection outcomes for the specific site
Competitive landscape: how hydrocortisone supply risks show up in the market
Hydrocortisone supply issues in practice tend to appear as:
- Sterile facility throughput constraints (injectables/ophthalmics)
- Formulation-specific excipient sourcing limits
- Batch release bottlenecks (sterility assurance testing, sterility retest timelines)
- Compendial specification drift (particle uniformity, dissolution for oral)
Key Takeaways
- Hydrocortisone supply is dosage-form–dependent; sterile injectables and ophthalmics have the narrowest qualified supplier pool.
- Procurement success relies on mapping the hydrocortisone API (DMF/ASMF support), the finished-dose manufacturer capability (topical vs solid vs sterile), and packaging/formulation constraints.
- The strongest qualification approach is evidence-based: GMP coverage, compendial compliance, batch traceability, validated process controls, and documented stability.
FAQs
- How do I identify hydrocortisone API DMF holders for my target dosage form?
- What manufacturing controls matter most for hydrocortisone sterile suspensions?
- Which excipient categories most commonly drive hydrocortisone topical formulation changes?
- How should procurement teams compare contract manufacturers for solid-dose hydrocortisone?
- What documentation is required to support hydrocortisone regulatory submissions when switching suppliers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
- FDA. Drug Master Files (DMF) database and guidance materials.
- European Medicines Agency (EMA). European public assessment reports and product information.
